http://www.ptemag.com/pharmtecheurope A publication featuring peer-reviewed technical articles on all aspects of pharmaceutical and biopharmaceutical manufacture. Subjects include solid dosage, drug delivery, packaging, raw materials, clean rooms and IT applications, supported by regulatory columns from Brussels and Washington. Information on products and literature used in drug manufacturing, as well as industry news, are also provided. 2008-05-17T10:12:50Z http://www.ptemag.com/pharmtecheurope/Latest+News/A-potent-treatment-for-autoimmune-diseases/ArticleStandard/Article/detail/516187?ref=25 An old therapy for a variety of autoimmune diseases is to be made more efficient thanks to 10 years of research. 2008-05-13T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/202008/516187null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/Advancing-respiratory-drug-development/ArticleStandard/Article/detail/516186?ref=25 An agreement between GE Healthcare and Merck & Co. to share technology on imaging in the lungs could help respiratory treatment development. 2008-05-13T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/202008/516186null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/Can-tomatoes-stop-us-from-ageing/ArticleStandard/Article/detail/514049?ref=25 Tomatoes could be the new weapon in the fight against sun damage, according to research conducted by two UK universities. 2008-05-06T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/514049null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/Europe-and-India-seek-improved-safety/ArticleStandard/Article/detail/514047?ref=25 A collaboration between Europe and India will strengthen efforts to improve the quality and safety of medicines in both locations, and will include the development of joint inspections of manufacturing sites. 2008-05-06T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/514047null HTML http://www.ptemag.com/pharmtecheurope/News/Bio-news/ArticleStandard/Article/detail/514486?ref=25 Pfizer has discontinued a Phase III clinical trial that was studying a potential treatment for advanced melanoma. The trial for tremelimumab was stopped as the drug seemed to be no better than standard chemotherapy. Initially, it was believed that the treatment could stimulate patients' immune systems to attack their tumours, even in melanoma patients. 2008-05-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/192008/514486null XML http://www.ptemag.com/pharmtecheurope/Project-Leader-Life-Cycle-Management/ArticleStandard/Article/detail/514941?ref=25 Project Leader Life Cycle Management 2008-05-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/192008/514941null PDF http://www.ptemag.com/pharmtecheurope/Editor%27s+comment/A-matter-of-perspective/ArticleStandard/Article/detail/514480?ref=25 One of the headlines before going to print was 'Pfizer earnings suffer as patent expiries cause damage'. This US pharma giant has reported a net income decline of 18% for the first quarter, despite the positive impact of the favourable currency rates. 2008-05-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/192008/514480null XML http://www.ptemag.com/pharmtecheurope/Outsourcing/China-captivates-the-clinical-trial-sector/ArticleStandard/Article/detail/514505?ref=25 2008-05-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/192008/514505null XML http://www.ptemag.com/pharmtecheurope/APIs/Tackling-waste-water-with-nanofiltration-membranes/ArticleStandard/Article/detail/514484?ref=25 The pharmaceutical industry must address the release of nonbiodegradable APIs into the environment. 2008-05-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/192008/514484/PTEJevons_flash.jpg XML http://www.ptemag.com/pharmtecheurope/Validation/The-recovery-mission-ndash-coping-with-validation-/ArticleStandard/Article/detail/514487?ref=25 Practical guidance on how to handle validation failures cannot be found in the existing literature because they are not supposed to happen. 2008-05-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/192008/514487/PTEKrause_flash.jpg XML http://www.ptemag.com/pharmtecheurope/News/News/ArticleStandard/Article/detail/514481?ref=25 Action has been taken following a recent report that revealed EU citizens had unequal access to health and medicines information. The European Commission (EC) is now planning to reform the rules regarding information provision to patients. 2008-05-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/192008/514481null XML http://www.ptemag.com/pharmtecheurope/Validation/The-counterfeit-problem/ArticleStandard/Article/detail/514483?ref=25 The assembly of the World Health Organisation (WHO) later this month is expected to feature counterfeit medicines as one of its important discussion points, and there is some hope that the ministers will agree on measures that will strengthen anticounterfeiting legislation and enforcement worldwide. 2008-05-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/192008/514483null XML http://www.ptemag.com/pharmtecheurope/Manufacturing+and+Processing/Current-status-in-buccal-drug-delivery/ArticleStandard/Article/detail/514485?ref=25 The adequate absorption and transport of drugs in the body is part of optimal therapy. Drug administration perorally is easy, common and traditional, but occasionally alternative routes are required. 2008-05-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/192008/514485/PTEGiannola_flash.jpg XML http://www.ptemag.com/pharmtecheurope/drug+delivery/Dawning-of-a-new-drug-delivery-era/ArticleStandard/Article/detail/514482?ref=25 Insulin is one of the world's oldest and most well-known biological drugs, and the need for it is not going to go away as the number of patients diagnosed with diabetes continues to increase. A wealth of clinical evidence shows that good, long-term glucose control in diabetes is key to avoiding complications such as kidney disease, blindness and heart problems. 2008-05-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/192008/514482null XML http://www.ptemag.com/pharmtecheurope/Validation/20th-Anniversary-Special-Feature-The-time-for-proc/ArticleStandard/Article/detail/514510?ref=25 When Pharmaceutical Technology Europe was established 20 years ago, PAT was not a hot topic in the industry. It was started in 2002 by FDA to modernize pharmaceutical manufacturing and increase the efficiency of manufacturing processes. 2008-05-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/192008/514510/main_main.jpg http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/192008/514510null XML http://www.ptemag.com/pharmtecheurope/Information+Technology/Managing-the-future/ArticleStandard/Article/detail/514488?ref=25 The adoption of computers into every aspect of the pharmaceutical industry has been enormous. Some estimates would put productivity and efficiency gains across the pharmaceutical industry at 2–3 times what they were previously. However, they are only just beginning to have an effect in the areas of training and document management, which have traditionally been managed by people and paper systems. With increasingly strict regulations and the growing complexity of processes and training requirements, there are even greater efficiency gains, as well as cost savings, to be achieved by adopting electronic document management systems (eDMS), learning management systems (LMS) and systems for the electronic signing of documents. 2008-05-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/192008/514488null XML http://www.ptemag.com/pharmtecheurope/Manufacturing+and+Processing/Getting-the-most-out-of-producing-therapeutic-biol/ArticleStandard/Article/detail/514516?ref=25 2008-05-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/192008/514516null XML http://www.ptemag.com/pharmtecheurope/Latest+News/British-university-research-under-threat/ArticleStandard/Article/detail/512910?ref=25 Pharma's extensive collaborative research links with the UK university science base are now under threat because of costs and issues regarding intellectual property ownership. 2008-04-29T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/512910null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/An-end-to-exchange-rate-concerns/ArticleStandard/Article/detail/512909?ref=25 Pharmaceutical companies are being offered the opportunity to purchase foreign currency up to 12 months before the money has to change hands, which could remove concerns regarding fluctuations in the currency market. 2008-04-29T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/512909null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/Has-pharma-run-out-of-treatments/ArticleStandard/Article/detail/511581?ref=25 Doctors are running out of treatments for trauma victims and critically ill patients because of infections from drug-resistant microbes, according to a speaker at the Society for General Microbiology's recent meeting in Edinburgh (UK). 2008-04-22T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/172008/511581null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/New-research-area-to-provide-new-treatments/ArticleStandard/Article/detail/511582?ref=25 Research into the link between allergies and the development of tumours has become an established research discipline that could have benefits for future cancer treatments. 2008-04-22T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/172008/511582null HTML http://www.ptemag.com/pharmtecheurope/Author-guidelines-2008/ArticleStandard/Article/detail/511336?ref=25 Author guidelines 2008 2008-04-21T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/172008/511336null PDF http://www.ptemag.com/pharmtecheurope/Latest+News/Two-percent-of-child-drug-trials-have-independent-/ArticleStandard/Article/detail/510076?ref=25 Research has revealed that only 2% of paediatric drug trials have independent safety monitoring committees that can aid the early detection of adverse drug reactions. 2008-04-15T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/162008/510076null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/Reddy-ly-entering-Europe/ArticleStandard/Article/detail/510077?ref=25 Two new European acquisitions will enhance Indian-based Dr Reddy?s generic pipeline and R&D infrastructure, which could lead to an increased number of cheaper medicines for patients. 2008-04-15T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/162008/510077null HTML http://www.ptemag.com/pharmtecheurope/PTE-May-Run-List-2008/ArticleStandard/Article/detail/509506?ref=25 PTE May run list 2008 2008-04-11T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/152008/509506null DOC http://www.ptemag.com/pharmtecheurope/PTE-June-2008-run-list/ArticleStandard/Article/detail/509507?ref=25 June 2008 PTE run list 2008-04-11T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/152008/509507null DOC http://www.ptemag.com/pharmtecheurope/Editorial-calendar-2008/ArticleStandard/Article/detail/509284?ref=25 Editorial calendar 2008 2008-04-10T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/152008/509284null PDF http://www.ptemag.com/pharmtecheurope/The-role-of-industrial-automation-in-qualified-bui/ArticleStandard/Article/detail/509267?ref=25 The role of industrial automation in qualified building automation solutions 2008-04-10T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/152008/509267null PDF http://www.ptemag.com/pharmtecheurope/Understanding-the-benefits-of-active-RFID-for-asse/ArticleStandard/Article/detail/509009?ref=25 Understanding the benefits of active RFID for asset tracking 2008-04-09T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/152008/509009null PDF http://www.ptemag.com/pharmtecheurope/Final-bulk-inspection-of-solid-dose-pharmaceutical/ArticleStandard/Article/detail/509047?ref=25 Final bulk inspection of solid-dose pharmaceuticals 2008-04-09T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/152008/509047null PDF http://www.ptemag.com/pharmtecheurope/Calibration-in-the-pharmaceutical-industry/ArticleStandard/Article/detail/509003?ref=25 Calibration in the pharmaceutical industry 2008-04-09T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/152008/509003null PDF http://www.ptemag.com/pharmtecheurope/How-often-should-instruments-be-calibrated/ArticleStandard/Article/detail/509005?ref=25 How often should instruments be calibrated? 2008-04-09T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/152008/509005null PDF http://www.ptemag.com/pharmtecheurope/enews-images/ArticleStandard/Article/detail/508312?ref=25 images 2008-04-08T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/152008/508312null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/Germanys-medical-engineering-milestone/ArticleStandard/Article/detail/507464?ref=25 The construction of northern Germany's first particle therapy clinic (PTC) will represent the largest public-private partnership project ever launched in the German healthcare sector and offer the possibility of new cancer therapies. 2008-04-08T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/142008/507464null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/Europes-counterfeit-crackdown/ArticleStandard/Article/detail/507462?ref=25 A range of measures, including a ban on repackaging, has been proposed to combat the increasing prevalence of counterfeit pharmaceuticals in Europe. 2008-04-08T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/142008/507462null HTML http://www.ptemag.com/pharmtecheurope/News/Bio-news/ArticleStandard/Article/detail/512623?ref=25 An alternative to controversial stem cell therapy could be provided by patented technology that extracts mature white blood cells from veins and turns them into cells with programmable properties comparable to those of stem cells. The technology was developed by Blasticon (Germany). 2008-04-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/512623null XML http://www.ptemag.com/pharmtecheurope/drug+delivery/Enhanced-brain-drug-delivery-and-targeting/ArticleStandard/Article/detail/512619?ref=25 The blood–brain barrier (BBB) forms an interface between the circulating blood and the brain, and functions as a tremendously effective barrier for the delivery of potential neurotherapeutics into the brain parenchyma. Conversely, the BBB possesses various carrier-mediated transport systems for the uptake of small molecules, such as essential nutrients and vitamins. These transporters have become an attractive target for drug/prodrug design in an attempt to ferry drug molecules across the BBB. Central nervous system (CNS) drug delivery is often limited by poor brain penetration of the potential drug candidate. As a result of its unique barrier properties, the BBB poses a huge challenge for the delivery of potential neurotherapeutics into the brain parenchyma.1 It is estimated that only 2% of small-molecule drugs and ,0.1% of novel protein and peptide pharmaceuticals developed for CNS diseases reach therapeutic concentrations in the brain.2,3 Many of the pharmacologically active drugs tend to fail.. 2008-04-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/512619null XML http://www.ptemag.com/pharmtecheurope/Manufacturing+and+Processing/Water-water-everywhere/ArticleStandard/Article/detail/512616?ref=25 The amount of water used by industry, including pharma and biotech manufacturing, amounts to 23% of the world's supplies 2008-04-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/512616null XML http://www.ptemag.com/pharmtecheurope/Editor%27s+comment/The-end-of-an-era/ArticleStandard/Article/detail/512614?ref=25 It is the end of an era. Building on more than 6 years of dedication and hard work, Gurminder Marwaha has left Pharmaceutical Technology Europe (PTE) in search of new challenges. As his successor, I would like to join all the members of the editorial team in wishing him every success. 2008-04-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/512614null XML http://www.ptemag.com/pharmtecheurope/Outsourcing/20th-Anniversary-Special-Feature-Outsourcing-biolo/ArticleStandard/Article/detail/512620?ref=25 Biopharmaceuticals are the most rapidly growing segment of the pharmaceuticals market. Developing and marketing biopharmaceuticals are huge roles in almost every major pharmaceutical company's strategy. However, they are extremely complex molecules and are highly sensitive to the manufacturing processes used to produce them. These processes require exquisite control of living production systems, making, without a doubt, biopharmaceuticals one of the most challenging products of any type to manufacture. 2008-04-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/512620null XML http://www.ptemag.com/pharmtecheurope/Supply+Chain/Out-of-Africa-the-pharma-challenge/ArticleStandard/Article/detail/512621?ref=25 Manufacturing facilities must be inspected by members of regulatory bodies. However… these bodies are woefully inadequate at performing the task. 2008-04-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/512621null XML http://www.ptemag.com/pharmtecheurope/Outsourcing/East-meets-West/ArticleStandard/Article/detail/512617?ref=25 Most CROs are entering China with expectations that a significant local market opportunity will develop as major pharmaceutical companies establish research development operations there... 2008-04-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/512617null XML http://www.ptemag.com/pharmtecheurope/Latest+News/Smaller-and-better/ArticleStandard/Article/detail/505090?ref=25 A high-density sensor array that is 10 times smaller than existing models could help improve disease diagnosis. 2008-04-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/132008/505090null HTML http://www.ptemag.com/pharmtecheurope/Dosage+Forms/Solid-dosage-forms-from-self-emulsifying-lipidic-f/ArticleStandard/Article/detail/512622?ref=25 Spraying techniques can be used to produce powder form formulations. The concept works by the adsorption/absorption of a liquid SELF onto a neutral carrier… 2008-04-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/512622null XML http://www.ptemag.com/pharmtecheurope/Supply+Chain/Developing-cold-chain-solutions/ArticleStandard/Article/detail/512632?ref=25 2008-04-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/512632null XML http://www.ptemag.com/pharmtecheurope/Biopharmaceuticals/The-role-of-analytical-science-in-the-debate-over-/ArticleStandard/Article/detail/512625?ref=25 As the US biopharmaceutical industry and regulators debate new requirements for biosimilars, industry leaders are turning to analytical science to define intellectual property and business development strategies. Emerging techniques are providing previously unseen protein characterization details, giving both innovator and generics companies new weapons in the battle for future market share. 2008-04-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/512625null XML http://www.ptemag.com/pharmtecheurope/Biopharmaceuticals/The-new-biopharmaceutical-blueprint/ArticleStandard/Article/detail/512624?ref=25 As a skipping stone creates ripples in a lake, SOA can help create benefits that quickly ripple through many other areas of the organization and partners. 2008-04-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/512624null XML http://www.ptemag.com/pharmtecheurope/News/News/ArticleStandard/Article/detail/512615?ref=25 Heparin, already responsible for deaths in the US, has now been tied to several adverse reactions in Germany, and there are now concerns that the heparin scare could become a global problem. In the US, the deaths were linked to heparin produced by Baxter, which has no link to Rotexmedica, where the German batches originated. 2008-04-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/512615null XML http://www.ptemag.com/pharmtecheurope/Biopharmaceuticals/Managing-initial-recovery-processes-with-multilaye/ArticleStandard/Article/detail/512633?ref=25 Monoclonal antibodies and recombinant proteins have increased their importance and gained success as therapeutic agents in the treatment of various diseases. 2008-04-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/512633null XML http://www.ptemag.com/pharmtecheurope/Latest+News/New-injections-mean-no-needles/ArticleStandard/Article/detail/505091?ref=25 A number of companies and research institutes in Germany are collaborating to develope a non-invasive vaccine that can be applied topically rather than by a needle. 2008-04-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/132008/505091null HTML http://www.ptemag.com/pharmtecheurope/Formulation/The-Problem-with-Stents/ArticleStandard/Article/detail/512618?ref=25 Our company is involved in developing and manufacturing APIs that can be utilized with drug-eluting stents (DES). Despite ensuring constancy in pharmaceutical composition, we are experiencing issues with variations in drug release during in vitro studies. We are working closely with a stent manufacturer to develop the system, but could surface analysis techniques investigate the problem further? 2008-04-01T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/182008/512618null XML http://www.ptemag.com/pharmtecheurope/Latest+News/Researchers-simulate-the-threat-of-a-pandemic-infl/ArticleStandard/Article/detail/503595?ref=25 An international group of researchers has determined how a pandemic influenza outbreak might travel through a large city, and whether it can be stopped before a large mortality rate is reached. 2008-03-25T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/122008/503595null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/165-new-jobs-for-Ireland/ArticleStandard/Article/detail/503268?ref=25 Teva Pharmaceuticals has invested approximately €65 million at its existing facility in Waterford (Ireland), which will create up to 165 positions in R&D, manufacturing, quality control and administrative and support services during the next 5 years. 2008-03-25T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/122008/503268null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/The-paradoxical-frog-151-a-treatment-for-diabetes/ArticleStandard/Article/detail/501603?ref=25 Secretions from the skin of a South American frog could be used to boost insulin production in people with Type 2 diabetes. 2008-03-18T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/112008/501603null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/Stem-cell-therapy-challenged-by-German-company/ArticleStandard/Article/detail/501605?ref=25 An alternative to controversial stem cell therapy could be provided by patented technology that extracts mature white blood cells from veins and turns them into cells with programmable properties comparable to those of stem cells. 2008-03-18T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/112008/501605null HTML http://www.ptemag.com/pharmtecheurope/Company-profile-151-Foss/ArticleStandard/Article/detail/501590?ref=25 FOSS NIRSystems, Inc. is the world leading supplier of laboratory, at-line and process NIR solutions for use in the pharmaceutical, chemical and petrochemical industries. 2008-03-17T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/112008/501590null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/Bacteriophage-battle-superbugs/ArticleStandard/Article/detail/499748?ref=25 Data presented on the first, fully-regulated clinical trial suggests that serious bacterial infections and superbugs can be combated with bacteriophage technology. 2008-03-11T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/102008/499748null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/Is-nanotechnology-morally-acceptable/ArticleStandard/Article/detail/499752?ref=25 According to survey results, Europeans and Americans have very different views on the morality of nanotechnology. 2008-03-11T04:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/102008/499752null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/Acquisition-strengthens-Pfizers-European-stronghol/ArticleStandard/Article/detail/494023?ref=25 Pfizer will acquire Encysive Pharmaceuticals Inc., a biopharmaceutical company whose product for the treatment of pulmonary arterial hypertension (PAH) is commercially available in much of the EU and is approved in other markets. 2008-03-04T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/092008/494023null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/Blocking-Sonic-Hedgehog-key-to-killing-cancer/ArticleStandard/Article/detail/494022?ref=25 Scientists have uncovered new research about how cancer cells grow ? and how they can be killed. 2008-03-04T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/092008/494022null HTML http://www.ptemag.com/pharmtecheurope/Chemspec-India-2008/ArticleStandard/Article/detail/494122?ref=25 Chemspec India 2008 is your opportunity to be part of India?s only dedicated event for custom, fine and speciality chemicals. 2008-03-04T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/092008/494122null HTML http://www.ptemag.com/pharmtecheurope/Manufacturing+and+Processing/A-stability-indicating-HPLC-procedure-for-determin/ArticleStandard/Article/detail/506144?ref=25 The stability of drugs in solid forms such as powders, tablets and capsules is usually determined very thoroughly by the drug's manufacturer. Based on stability study data, the shelf-life of a drug substance or a drug product is assigned. In addition to dispensing solid dosage forms to patients, pharmacists are frequently asked to compound oral liquid preparations for which the shelf-life or beyond-use date are assigned based on the pharmacist's best judgment — often without the benefit of stability data. 2008-03-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/132008/506144null XML http://www.ptemag.com/pharmtecheurope/Formulation/The-challenge-of-21st-century-influenza/ArticleStandard/Article/detail/506141?ref=25 Conventional influenza vaccines use an egg-based culture and harvest process. This is slow and inflexible compared with emerging cell culture-based approaches that respond rapidly to the influenza virus's inherent ability to 'drift' or, more dangerously, 'shift' — a critical factor that would arise in the event of a pandemic. 2008-03-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/132008/506141null XML http://www.ptemag.com/pharmtecheurope/Primary+Packaging/20th-Anniversary-Special-Feature-Two-decades-of-pa/ArticleStandard/Article/detail/506142?ref=25 Twenty years ago it was commonplace for pills, tablets and capsules to come in small, plastic or even glass bottles. Syrups were a much more common galenic solution than today, and individual dosages of injectables were only offered in glass vials and ampoules. 2008-03-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/132008/506142null XML http://www.ptemag.com/pharmtecheurope/Outsourcing/Outsourcing-still-the-way-forward/ArticleStandard/Article/detail/506146?ref=25 During the past two decades, outsourcing has become increasingly prevalent as the way to gain competitive advantage. This trend has led to a significant increase in the number of services and functions available for outsourcing, and there are emerging opportunities for niche outsourcing to contractors that provide specialized sets of tools and access to cutting-edge technology. 2008-03-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/132008/506146null XML http://www.ptemag.com/pharmtecheurope/Outsourcing/Indias-CRO-sector-on-the-rise/ArticleStandard/Article/detail/506157?ref=25 2008-03-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/132008/506157null XML http://www.ptemag.com/pharmtecheurope/Regulatory/Europe-overshadowed-by-China-and-the-US/ArticleStandard/Article/detail/506158?ref=25 2008-03-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/132008/506158null XML http://www.ptemag.com/pharmtecheurope/News/News/ArticleStandard/Article/detail/506139?ref=25 Selective reporting of antidepressant drug trials; SAFC Pharma expands solid state chemistry services; New facility for key cancer treatment 2008-03-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/132008/506139null XML http://www.ptemag.com/pharmtecheurope/Outsourcing/Supporting-critical-Phase-IndashIV-clinical-studie/ArticleStandard/Article/detail/506145?ref=25 The pharmaceutical industry has experienced a number of difficulties during recent years. Greater competition from generics (more than 60% of prescription drugs are supplied from the generic market) and increased gaps in the drug pipeline that result in acquisitions or strategic alliances has led to a feeling of uncertainty in the bio/pharma marketplace. There have also been changes in the marketplace with a shift from primary care to specialty drugs, the introduction of personalized medicine driving the need for biomarker/diagnostic technology and the introduction of biopharmaceuticals. 2008-03-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/132008/506145null XML http://www.ptemag.com/pharmtecheurope/Manufacturing+and+Processing/Automation-works/ArticleStandard/Article/detail/506140?ref=25 My personal experience of lab automation is limited to supervising a peptide synthesiser back in the late 1980s. The machine was eye-wateringly expensive — but it was soon paying its way in terms of productivity and research publications. So if I were a stake-holder in a company pondering whether to invest in a well-designed gadget that could automate a routine operation, I'd say: 'go for it'. 2008-03-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/132008/506140null XML http://www.ptemag.com/pharmtecheurope/PAT/Making-data-analysis-lean/ArticleStandard/Article/detail/506143?ref=25 Six sigma, process analytical technology (PAT) and related initiatives are driving greater use of statistical analysis methods to increase process understanding and improve manufacturing capabilities. 2008-03-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/132008/506143null XML http://www.ptemag.com/pharmtecheurope/Latest+News/New-class-of-asthma-and-allergy-drugs-close-at-han/ArticleStandard/Article/detail/492286?ref=25 An important target that holds significant promise for millions of people suffering from allergies, asthma, rheumatoid arthritis and a range of other inflammatory diseases has been found. 2008-02-26T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/082008/492286null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/Europes-first-intradermal-microinjection-system/ArticleStandard/Article/detail/492284?ref=25 A marketing authorization application has been submitted and accepted for review by the EMEA for the first time for a product that will use an intradermal microinjection system that is barely perceptible when it enters the skin. 2008-02-25T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/082008/492284null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/Bio-succinic-acid-saves-money-and-the-environment/ArticleStandard/Article/detail/490620?ref=25 Biorenewabale succinic acid could provide energy savings of 30?40% compared with traditional chemical processes, saving companies money while having a positive effect on the environment. 2008-02-11T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/072008/490620null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/Antismoking-vaccines-151-a-breath-of-fresh-air-to-/ArticleStandard/Article/detail/490619?ref=25 The launch of two promising pipeline nicotine vaccines could boost the prescription nicotine dependence market and help millions of smokers to kick their habit. 2008-02-11T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/072008/490619null HTML http://www.ptemag.com/pharmtecheurope/State-of-the-art-laboratory-opened-in-Maryland/ArticleStandard/Article/detail/488814?ref=25 Azopharma has announced the opening of a state-of-the-art laboratory and a new acquisition that will expand and improve the group?s ability to support drug development and commercialization. 2008-02-04T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/062008/488814null HTML http://www.ptemag.com/pharmtecheurope/EBD-event-profile-BIO-Europe-Spring-2008/ArticleStandard/Article/detail/488593?ref=25 The BIO-Europe Spring event brings together international decision-makers from all sectors of the biotechnology industry, and features the successful combination of one-on-one meetings, company presentations and a lively exhibition. 2008-02-03T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/052008/488593null HTML http://www.ptemag.com/pharmtecheurope/Manufacturing+and+Processing/20th-Anniversary-Special-Feature-Robot-remedies-fo/ArticleStandard/Article/detail/500449?ref=25 Robotization of end-of-line packaging systems enables manufacturers to maintain high production rates while accommodating flexible and varied product packaging requirements. 2008-02-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/102008/500449null XML http://www.ptemag.com/pharmtecheurope/Manufacturing+and+Processing/Irish-pharma-mdash-looking-to-the-future/ArticleStandard/Article/detail/500447?ref=25 Deciding where in the world to locate a new plant is a key decision for any pharma or biotech company — and there has never been more choice. Europe and the US now compete with the Far East and India, and what about the new EU states? Might Lithuania or Estonia turn out to offer advantages compared with France or Germany when it comes to finding the best place to take a new drug forward to the market place? 2008-02-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/102008/500447null XML http://www.ptemag.com/pharmtecheurope/Formulation/Tablet-discolouration/ArticleStandard/Article/detail/500448?ref=25 We are currently experiencing a problem with one of our tablet lines. While the tablets appear white immediately after manufacture, after a time many of the tablets begin to take on a yellowish appearance. Could this be an issue that surface analysis could help resolve? 2008-02-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/102008/500448null XML http://www.ptemag.com/pharmtecheurope/Outsourcing/Asian-CMOs-becoming-global-leaders/ArticleStandard/Article/detail/500446?ref=25 As globalization of drug development and manufacturing gathered steam in the early part of this decade, many pharmaceutical companies in the newly-favoured regions of Asia, Eastern Europe and Latin America added contract services as adjuncts to their generic API and dosage form businesses. These new units, which in India are known under the unfortunate acronym of CRAMS (contract research and manufacturing services), were opportunistic responses to the growing outsourcing trends. Unfortunately, in many cases, they were not truly strategic commitments to the services business. 2008-02-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/102008/500446null XML http://www.ptemag.com/pharmtecheurope/Formulation/Transdermal-film-containing-nicotine-and-bupropion/ArticleStandard/Article/detail/500852?ref=25 2008-02-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/102008/500852null XML http://www.ptemag.com/pharmtecheurope/Pharmacokinetics-of-insulin-aerosols-generated-by-/ArticleStandard/Article/detail/500871?ref=25 2008-02-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/102008/500871null XML http://www.ptemag.com/pharmtecheurope/Biopharmaceuticals/Cycle-development-for-hydrogen-peroxide-clean-room/ArticleStandard/Article/detail/500450?ref=25 As part of a major project to design and build a new bulk vaccine antigen plant, the authors were asked to investigate and implement a suitable fumigation system for clean room decontamination. The facility was designed to handle and contain live influenza virus, and has clean room suites designed to containment levels CL2 and CL3 according to the Approved Code Of Practice and Guidance (ACOP, Control of Substances Hazardous to Health 4th Edition). From the outset, specific areas within the facility were identified as requiring fumigation and this formed part of the initial design brief. 2008-02-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/102008/500450null XML http://www.ptemag.com/pharmtecheurope/Manufacturing+and+Processing/Recent-developments-in-dry-coating/ArticleStandard/Article/detail/500868?ref=25 2008-02-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/102008/500868null XML http://www.ptemag.com/pharmtecheurope/Editor%27s+comment/Credit-crunch-bites-RampD/ArticleStandard/Article/detail/500444?ref=25 A possible recession in the US and a global credit crunch are going to be major factors in the amount of money available as shareholders tighten their purse-strings. 2008-02-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/102008/500444null XML http://www.ptemag.com/pharmtecheurope/News/News/ArticleStandard/Article/detail/500445?ref=25 The European Commission has launched a sector inquiry after recent reports revealed a significant decline in FDA drug approvals. The European commissioner of competition, Neelie Kroes, says: "Patent protection has never been stronger, but the number of new pharmaceuticals coming-to-market is declining. Patents can sometimes be invented around, and will always expire eventually, but generic manufacturers are not jumping into the markets as quickly as we would expect." 2008-02-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/102008/500445null XML http://www.ptemag.com/pharmtecheurope/Counterfeit-drugs-could-be-a-global-disaster/ArticleStandard/Article/detail/487442?ref=25 America?s Watchdog believes that the threat of counterfeit drugs could cause ?another global disaster? and is urging legitimate drug manufacturers to take the subject more seriously. 2008-01-28T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/052008/487442null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/Animals-reduced-in-toxicity-testing/ArticleStandard/Article/detail/487440?ref=25 Thousands of rodents have been spared from drug testing after a review deemed a particular toxicity test as ?unnecessary?. 2008-01-28T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/052008/487440null HTML http://www.ptemag.com/pharmtecheurope/Collaboration-to-combat-cancer/ArticleStandard/Article/detail/485356?ref=25 A new partnership is set to aid the R&D and commercialization of Toll-like Receptor 9 (TLR9) agonists for the treatment of cancer. 2008-01-18T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/032008/485356null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/Pharmas-quick-fix-not-necessarily-a-cure-all/ArticleStandard/Article/detail/487489?ref=25 Companies turning to licensing to fill pipeline gaps need to be aware that the practice has its own hazards and risks. 2008-01-18T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/052008/487489null HTML http://www.ptemag.com/pharmtecheurope/IMA-acquires-leading-freeze-drying-business/ArticleStandard/Article/detail/485357?ref=25 IMA firmly believes that its latest acquisition will enable it to strengthen its abilities in automatic packing machines for the pharmaceutical industry, and become a sole provider of complete solutions. 2008-01-18T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/032008/485357null HTML http://www.ptemag.com/pharmtecheurope/Biomedical-innovation-across-Europe/ArticleStandard/Article/detail/485355?ref=25 The Council of the EU has adopted the Innovative Medicines Initiative (IMI), a programme that aims to address the key ?bottlenecks? in the biomedical R&D process. With a budget of ?2 million, it will fund pan-European public?private partnerships in biomedical research. 2008-01-18T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/032008/485355null HTML http://www.ptemag.com/pharmtecheurope/Catalent-Pharma-Solutions/ArticleStandard/Article/detail/485532?ref=25 Catalent Pharma Solutions is one of the leading providers of advanced dose form and packaging technologies as well as development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. 2008-01-18T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/032008/485532null HTML http://www.ptemag.com/pharmtecheurope/Plan-to-market-pandemic-influenza-solution/ArticleStandard/Article/detail/485354?ref=25 A collaboration between Ge Healthcare (UK) and Novavex (MD, USA) seeks to increase manufacturing capacity and vaccine stockpiles to counter the threat of a global avian flu pandemic. 2008-01-18T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/032008/485354null HTML http://www.ptemag.com/pharmtecheurope/Beamex-CMX-calibration-software/ArticleStandard/Article/detail/485541?ref=25 Beamex calibration solutions, such as the Beamex CMX calibration software, improve performance in pharmaceutical companies in terms of safety and profitability. 2008-01-18T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/032008/485541null HTML http://www.ptemag.com/pharmtecheurope/Latest+News/BMS-to-close-second-Puerto-Rico-plant/ArticleStandard/Article/detail/487490?ref=25 Within the space of a few months, Bristol-Myers Squibb (BMS) has decided to close another manufacturing site in Puerto Rico to reduce costs. 2008-01-18T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/052008/487490null HTML http://www.ptemag.com/pharmtecheurope/Editor%27s+comment/Happy-Birthday/ArticleStandard/Article/detail/483076?ref=25 As the saying goes, actions speak louder than words, and I hope the features in this month's magazine provide you with examples of how others in the industry are playing their role in a greener future. 2008-01-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/022008/483076null XML http://www.ptemag.com/pharmtecheurope/Manufacturing+and+Processing/Centre-of-attraction/ArticleStandard/Article/detail/483085?ref=25 The pharmaceutical industry in Asia is gearing up to be at the centre of the global market. Most pharmaceutical companies in the region expect this shift to happen fast. Not only is Asia set to become the largest pharmaceutical market in the world, but many Asian territories will be the powerhouses of the industry. By 2020, the worldwide pharmaceuticals market could be worth around $1.3 trillion, with China being the second or third biggest market. 2008-01-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/022008/483085null XML http://www.ptemag.com/pharmtecheurope/The-foundations-of-success/ArticleStandard/Article/detail/508084?ref=25 Croatia's central postion at the crossroads of Europe and its long tradition in creative science are the basis for a potentially huge pharmaceutical industry. 2008-01-01T05:00:00Z http://www.ptemag.com/pharmtecheurope/data/articlestandard/pharmtecheurope/152008/508084null REMOTE